EA202090218A1 - Антитела к b7-h4 и способы их применения - Google Patents

Антитела к b7-h4 и способы их применения

Info

Publication number
EA202090218A1
EA202090218A1 EA202090218A EA202090218A EA202090218A1 EA 202090218 A1 EA202090218 A1 EA 202090218A1 EA 202090218 A EA202090218 A EA 202090218A EA 202090218 A EA202090218 A EA 202090218A EA 202090218 A1 EA202090218 A1 EA 202090218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antigen
human
binding fragments
specifically bind
Prior art date
Application number
EA202090218A
Other languages
English (en)
Inventor
Чарльз Каплан
Деррик Хаусер
Луис Боргес
Глория Браттич
Дэвид Белловин
Фелисия Кемп
Маджид ГХОДДУСИ
Нельс П. Нильсон
Кэти Миллер
Майки Шмидт
Original Assignee
Файв Прайм Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Файв Прайм Терапьютикс, Инк. filed Critical Файв Прайм Терапьютикс, Инк.
Priority claimed from PCT/US2018/047805 external-priority patent/WO2019040780A1/en
Publication of EA202090218A1 publication Critical patent/EA202090218A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Данное изобретение относится к антителам и их антигенсвязывающим фрагментам, которые специфически связываются с В7-Н4 человека (и необязательно В7-Н4 яванского макака (Cynomolgus), мыши и/или крысы), и к композициям, содержащим такие антитела или их антигенсвязывающие фрагменты. В конкретном аспекте указанные антитела или их антигенсвязывающие фрагменты, которые специфически связываются с В7-Н4 человека, усиливают пролиферацию Т-клеток, увеличивают продукцию интерферона-гамма и/или деплетируют экспрессирующие В7-Н4 клетки посредством активности АЗКЦ. Данное изобретение также обеспечивает способы лечения расстройств, таких как рак, путем введения антитела или его антигенсвязывающего фрагмента, которые специфически связываются с В7-Н4 человека.
EA202090218A 2018-04-12 2018-08-23 Антитела к b7-h4 и способы их применения EA202090218A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656789P 2018-04-12 2018-04-12
PCT/US2018/047805 WO2019040780A1 (en) 2017-08-25 2018-08-23 ANTI-B7-H4 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
EA202090218A1 true EA202090218A1 (ru) 2020-07-21

Family

ID=71833553

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090218A EA202090218A1 (ru) 2018-04-12 2018-08-23 Антитела к b7-h4 и способы их применения

Country Status (1)

Country Link
EA (1) EA202090218A1 (ru)

Similar Documents

Publication Publication Date Title
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
EA202091747A1 (ru) Составы антитела b7-h4
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
Wang et al. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
RU2013102596A (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРМАБЕЛЬНОЙ ОБЛАСТЬЮ α-ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
EA202092460A1 (ru) Антитела к ox40 и способы применения
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX2022011951A (es) Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
EA202091569A1 (ru) Моноклональные антитела и способы их применения
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EA202090218A1 (ru) Антитела к b7-h4 и способы их применения
EA200900991A1 (ru) Новые антитела против igf-1r
MX2022014243A (es) Proteina de union al antigeno st2.
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.